OL
OLY1.F Olympus Corporation
- Market cap
- EUR 10.6B
- P/E
- 21.7x
- P/B
- 2.44x
- ROE
- 8.4%
- Dividend yield
- 1.65%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is OLY1.F undervalued?
Graham numberOLY1.F trades 53.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Olympus Corporation fundamental analysis
No fundamental analysis for Olympus Corporation yet.
Olympus Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Olympus Corporation
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, "Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, su…
Full company profileOlympus Corporation financial statements
Olympus Corporation annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 748B | 786B | 794B | 797B | 731B | 869B | 882B | 926B | 997B | 1.01T |
| Gross Profit | 491B | 510B | 510B | 500B | 460B | 572B | 597B | 618B | 684B | 654B |
| Operating Income | 76.5B | 81.1B | 27.7B | 83.0B | 81.4B | 152B | 186B | 51.7B | 162B | 101B |
| EBITDA | - | 137B | 89.1B | 154B | 143B | 220B | 257B | 120B | 232B | 171B |
| Net Income | 78.2B | 57.1B | 8.15B | 51.7B | 12.9B | 116B | 143B | 243B | 118B | 68.2B |
| EPS | 57 | 42 | 5.97 | 40 | 10 | 91 | 114 | 208 | 104 | 62 |
| Balance Sheet | ||||||||||
| Total Assets | 991B | 979B | 932B | 1.02T | 1.18T | 1.36T | 1.51T | 1.53T | 1.43T | 1.54T |
| Total Liabilities | 560B | 534B | 490B | 644B | 786B | 847B | 867B | 777B | 681B | 725B |
| Shareholders' Equity | 429B | 443B | 441B | 371B | 394B | 510B | 640B | 757B | 752B | 812B |
| Cash & Short-term Investments | 199B | 191B | 114B | 162B | 217B | 303B | 169B | 341B | 253B | 188B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 90.2B | 95.1B | 66.9B | 134B | 124B | 170B | 98.5B | 42.4B | 190B | 101B |
| Capital Expenditure | 43.5B | 48.9B | 47.1B | 37.8B | 38.7B | 41.7B | 47.6B | 64.6B | 65.2B | 82.4B |
| Free Cash Flow | - | 31.7B | 5.48B | 67.6B | 64.9B | 108B | 27.9B | -22.3B | 125B | 18.2B |
| Ratios | ||||||||||
| ROE | 18.2% | 12.9% | 1.8% | 13.9% | 3.3% | 22.7% | 22.4% | 32.0% | 15.7% | 8.4% |
| ROA | 7.9% | 5.8% | 0.9% | 5.1% | 1.1% | 8.5% | 9.5% | 15.8% | 8.2% | 4.4% |
| Net Profit Margin | 10.5% | 7.3% | 1.0% | 6.5% | 1.8% | 13.3% | 16.3% | 26.2% | 11.8% | 6.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Olympus Corporation dividends
- Dividend yield
- 1.65%
- Forward dividend
- 0.17 EUR
- Payout ratio
- 33.1%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 22.6B | 20 | 33.1% |
| 2025 | JPY 21.0B | 19 | 17.8% |
| 2024 | JPY 20.1B | 17 | 8.3% |
| 2023 | JPY 17.8B | 14 | 12.4% |
| 2022 | JPY 15.4B | 12 | 13.3% |
| 2021 | JPY 12.9B | 10.00 | 99.5% |
| 2020 | EUR 10.2B | 7.97 | 19.8% |
| 2019 | EUR 9.56B | 7.00 | 117.3% |
| 2018 | EUR 9.58B | 7.02 | 16.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Mar 27, 2019.
Who owns Olympus Corporation
- Insiders 4.22%
- Institutions 61.91%
- Public & others 33.87%
- Shares outstanding 1.06B
- Free float 1.06B
Olympus Corporation company profile
- Company name
- Olympus Corporation
- Ticker
- OLY1.F
- ISIN
- JP3201200007
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 28,138
- Fiscal year end
- March
- Address
- 2951 Ishikawa-machi, Hachioji, Japan, 192-8507
- Phone
- 81 42 642 2111
- Website
- olympus.co.jp
About Olympus Corporation
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, "Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology products. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.
Olympus Corporation management
10- Mr. Robert John WhiteRepresentative Executive Officer, President, CEO & Director · born 1962
- Mr. Syed Mukarram NaveedExecutive Officer & CTO · born 1973
- Mr. Neil Boyden TannerExecutive Officer & Global General Counsel · born 1971
- Mr. Frank DrewalowskiSenior Advisor to Chief Executive Officer · born 1965
- Ms. Gabriela Castillo KaynorExecutive Officer, Chief Strategy Officer & ESG Officer · born 1975
- Mr. John Manfred de CsepelExecutive Officer & Chief Medical Officer · born 1964
- Mr. Michael Angelo ParentiCFO & Executive Officer · born 1977
- Takayuki AoyagiVice President of Accounting
- Stephen KneeboneCorporate Officer & Chief Information Officer
- Mr. Takaaki SakuraiVice President of Investor Relations